AbbVie Inc (ABBV)vsAnbio Biotechnology Class A Ordinary Shares (NNNN)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
NNNN
Anbio Biotechnology Class A Ordinary Shares
$6.34
-2.61%
HEALTHCARE · Cap: $283.98M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 744522% more annual revenue ($64.39B vs $8.65M). NNNN leads profitability with a 74.1% profit margin vs 9.8%. NNNN trades at a lower P/E of 43.1x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
NNNN
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Intrinsic value data unavailable for NNNN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Keeps 74 of every $100 in revenue as profit
Strong operational efficiency at 59.1%
Revenue surging 73.9% year-over-year
Every $100 of equity generates 24 in profit
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Trading at 9.2x book value
2.8% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : NNNN
The strongest argument for NNNN centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 74.1% and operating margin at 59.1%. Revenue growth of 73.9% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : NNNN
The primary concerns for NNNN are Price/Book, EPS Growth, Market Cap. A P/E of 43.1x leaves little room for execution misses.
Key Dynamics to Monitor
ABBV profiles as a value stock while NNNN is a growth play — different risk/reward profiles.
NNNN is growing revenue faster at 73.9% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 51/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Anbio Biotechnology Class A Ordinary Shares
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. The company is headquartered in Frankfurt am Main, Germany.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?